A urinary tissue inhibitor of metalloproteinases-2 (TIMP-2), a validated biomarker for AKI, was reported to predict the occurrence and duration of DGF in DCD KTx recipients [39]. The gene discussed is TIMP2; the disease is acute kidney injury.